Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Gains from Sales and Divestitures (2020 - 2022)

Cullinan Therapeutics has reported Gains from Sales and Divestitures over the past 3 years, most recently at $46.0 for Q4 2022.

  • Quarterly results put Gains from Sales and Divestitures at $46.0 for Q4 2022, down 99.98% from a year ago — trailing twelve months through Dec 2022 was $46.0 (down 99.98% YoY), and the annual figure for FY2022 was $46.0, down 99.98%.
  • Gains from Sales and Divestitures for Q4 2022 was $46.0 at Cullinan Therapeutics, down from $275000.0 in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for CGEM hit a ceiling of $275000.0 in Q4 2021 and a floor of $46.0 in Q4 2022.
  • Median Gains from Sales and Divestitures over the past 3 years was $128358.0 (2020), compared with a mean of $134468.0.
  • Biggest five-year swings in Gains from Sales and Divestitures: soared 114.24% in 2021 and later plummeted 99.98% in 2022.
  • Cullinan Therapeutics' Gains from Sales and Divestitures stood at $128358.0 in 2020, then soared by 114.24% to $275000.0 in 2021, then plummeted by 99.98% to $46.0 in 2022.
  • The last three reported values for Gains from Sales and Divestitures were $46.0 (Q4 2022), $275000.0 (Q4 2021), and $128358.0 (Q4 2020) per Business Quant data.